Aprilbio Co. Ltd.
AprilBio Co., Ltd. develops long-acting type biobetter and antibody biologics. The company develops antibody drugs, double antibodies, long-acting antibody drugs, long-acting protein drugs, and ADC-applied antibodies. It is developing various products for use in the treatment of rare diseases, cancer, male infertility, autoimmune and inflammatory diseases. The company was founded in 2013 and is h… Read more
Aprilbio Co. Ltd. (397030) - Net Assets
Latest net assets as of September 2025: ₩90.41 Billion KRW
Based on the latest financial reports, Aprilbio Co. Ltd. (397030) has net assets worth ₩90.41 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩97.02 Billion) and total liabilities (₩6.62 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩90.41 Billion |
| % of Total Assets | 93.18% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 30.24 |
Aprilbio Co. Ltd. - Net Assets Trend (2020–2024)
This chart illustrates how Aprilbio Co. Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Aprilbio Co. Ltd. (2020–2024)
The table below shows the annual net assets of Aprilbio Co. Ltd. from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩90.99 Billion | +57.56% |
| 2023-12-31 | ₩57.75 Billion | -16.50% |
| 2022-12-31 | ₩69.16 Billion | +20.99% |
| 2021-12-31 | ₩57.17 Billion | +514.92% |
| 2020-12-31 | ₩-13.78 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Aprilbio Co. Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5579678556000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩22.44 Billion | 24.66% |
| Other Components | ₩140.90 Billion | 154.86% |
| Total Equity | ₩90.99 Billion | 100.00% |
Aprilbio Co. Ltd. Competitors by Market Cap
The table below lists competitors of Aprilbio Co. Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shenzhen Newway Photomask Making Co. Ltd. A
SHG:688401
|
$679.21 Million |
|
Xiamen Anne Corp Ltd
SHE:002235
|
$679.45 Million |
|
Zhejiang Construction Investment Group Co Ltd
SHE:002761
|
$679.46 Million |
|
Sumitomo Osaka Cement Co. Ltd
F:SU2
|
$679.54 Million |
|
Almirall S.A
PINK:LBTSF
|
$678.91 Million |
|
Hangzhou Steam Turbine
SHE:200771
|
$678.61 Million |
|
Equitas Small Finance Bank Limited
NSE:EQUITASBNK
|
$678.10 Million |
|
Wereldhave N.V
PINK:WRDEF
|
$678.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Aprilbio Co. Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 57,747,482,130 to 90,987,762,160, a change of 33,240,280,030 (57.6%).
- Net income of 20,005,162,290 contributed positively to equity growth.
- Share repurchases of 1,098,020,540 reduced equity.
- New share issuances of 1,098,020,540 increased equity.
- Other factors increased equity by 13,235,117,740.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩20.01 Billion | +21.99% |
| Share Repurchases | ₩1.10 Billion | -1.21% |
| Share Issuances | ₩1.10 Billion | +1.21% |
| Other Changes | ₩13.24 Billion | +14.55% |
| Total Change | ₩- | 57.56% |
Book Value vs Market Value Analysis
This analysis compares Aprilbio Co. Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 15.71x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | ₩-657.58 | ₩63700.00 | x |
| 2021-12-31 | ₩2718.35 | ₩63700.00 | x |
| 2022-12-31 | ₩3274.38 | ₩63700.00 | x |
| 2023-12-31 | ₩2676.69 | ₩63700.00 | x |
| 2024-12-31 | ₩4055.51 | ₩63700.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Aprilbio Co. Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 21.99%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 72.71%
- • Asset Turnover: 0.28x
- • Equity Multiplier: 1.09x
- Recent ROE (21.99%) is above the historical average (-21.53%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | ₩-8.84 Billion |
| 2021 | -92.21% | -225.31% | 0.38x | 1.07x | ₩-58.43 Billion |
| 2022 | -12.95% | -4479.64% | 0.00x | 1.03x | ₩-15.88 Billion |
| 2023 | -24.47% | 0.00% | 0.00x | 1.38x | ₩-19.90 Billion |
| 2024 | 21.99% | 72.71% | 0.28x | 1.09x | ₩10.91 Billion |
Industry Comparison
This section compares Aprilbio Co. Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Aprilbio Co. Ltd. (397030) | ₩90.41 Billion | 0.00% | 0.07x | $678.93 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |